Safety of Bivalirudin during percutaneous coronary interventions in patients with abnormal renal function

International Journal of Cardiovascular Interventions

Volumn 7, Issue 2, 2005, Pages 88-92

  Roguin, Ariel ^a   Steinberg, Benjamin A ^a   Watkins III, Stanley P ^a   Resar, Jon R ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIRULOG; THROMBIN INHIBITOR;

ADULT; AGED; ARTICLE; BLEEDING; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; RISK FACTOR; SEX DIFFERENCE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTITHROMBINS; COMORBIDITY; CORONARY DISEASE; CREATININE; FEMALE; HEMORRHAGE; HIRUDINS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RISK FACTORS;

EID: 23944508009     PISSN: 14628848     EISSN: None     Source Type: Journal    
DOI: 10.1080/14628840510011298     Document Type: Article

References (13)

1. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J. 2002;143:847-53.
2. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade compared with Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention. REPLACE-2 Randomized Trial. JAMA. 2003;289:853-63.
3. Robson R, White H, Aylward P, Framptom C. Bivalirudin pharmacokinetics and pharmacodynamics: Effect of renal function, dose and gender. Clin Pharmacol Ther. 2002;71:433-9.
4. Steinhubl SR. Percutaneous coronary interventions in patients with renal insufficiency: A high-risk, under-studied cohort. Am Heart J. 2003;146:213-4.
5. Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol. 2000;12(Suppl F): 33F-6.
6. Reddan D, Szczech LA, O'Shea S, Califf RM. Anticoagulation in acute cardiac care in patients with chronic kidney disease. Am Heart J. 2003;145:586-94.
7. White H. The Hirulog and early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001;358:1855-63.
8. Chew DP, Bhatt DL, Kimball W, et al. Bivalirudin provides increasing benefit with decreasing renal function: A meta-analysis of randomized trials. Am J Cardiol. 2003;92:919-23.
9. Best PJM, Lennon R, Gersh BJ, et al. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J. 2003;146:345-50.
10. Jeremias A, Bhatt DL, Chew DP, et al. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. Am J Cardiol. 2002;89:1209-11.
11. Rubenstein MH, Harrell LC, Sheynberg BV, et al. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation. 2000;102:2966-72.
12. Reddan DN, O'Shea JC, Sarembock, IJ. Treatment Effects of Eptifibatide in Planned Coronary Stent Implantation in Patients With Chronic Kidney Disease (ESPRIT Trial). Am J Cardiol. 2003;91:17-21.
13. Seybert AL. Bivalirudin administration during percutaneous coronary intervention: emphasis on high-risk patients. Pharmacotherapy. 2002;22:112S-8S.